# LA-HCM Study : Rivaroxaban for Antithrombotic Prevention in Hypertrophic Cardiomyopathy Patients With Abnormal Left Atrial Strain.

Study · id `cardio:ct-nct07202897` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07202897](<https://clinicaltrials.gov/study/NCT07202897>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT07202897

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 532 participants.

## Technical summary

Registry record NCT07202897. Randomized; no masking; primary purpose prevention. Start 2026-01-07 (actual); primary completion 2032-01-07 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose prevention
- Phase: Phase 3
- Enrolled: 532 participants (planned count; ClinicalTrials.gov record NCT07202897, source copy `cardio:ctgov-nct07202897-2026-06-12`, retrieved 2026-10-31)
- Started: 2026-01-07 (actual) (ClinicalTrials.gov record NCT07202897, source copy `cardio:ctgov-nct07202897-2026-06-12`, retrieved 2026-10-31)
- Primary completion: 2032-01-07 (anticipated) (ClinicalTrials.gov record NCT07202897, source copy `cardio:ctgov-nct07202897-2026-06-12`, retrieved 2026-10-31)
- Completion: 2033-01-07 (anticipated) (ClinicalTrials.gov record NCT07202897, source copy `cardio:ctgov-nct07202897-2026-06-12`, retrieved 2026-10-31)
- Countries: France (ClinicalTrials.gov record NCT07202897, source copy `cardio:ctgov-nct07202897-2026-06-12`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07202897-2026-06-12`, retrieved 2026-10-31)

## The registry's words

- Brief title: LA-HCM Study : Rivaroxaban for Antithrombotic Prevention in Hypertrophic Cardiomyopathy Patients With Abnormal Left Atrial Strain.
- Acronym: LA-HCM
- Condition: Hypertrophic Cardiomyopathy (HCM)
- Intervention (Drug): Anticoagulant treatment Rivaroxaban
- Intervention (Other): Best medical therapy
- Lead sponsor: Rennes University Hospital
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Cardiomyopathy (heart muscle disease) (`cardio:cardiomyopathy`)
- Registry condition terms include this condition: Hypertrophic cardiomyopathy (`cardio:hypertrophic-cardiomyopathy`)
- Registry lists this organization as the lead sponsor: Rennes University Hospital (`cardio:org-rennes-university-hospital`)

## Provenance

Content hash: 1a9df0cc02bd3fefd59acdbc8c8d0c3781dbc3ee0fda6baea3548c224b611622
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
